AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11561074
Drug: Butorphanol (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (1.5, 3, and 6 mg/70 kg)
Trial: 7821310
Drug: L-acetylcarnitine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine (30 mg x kg)
Trial: 7821310
Drug: L-propionylcarnitine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionylcarnitine (30 mg x kg)
Trial: 7821310
Drug: Nitroglycerin (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (1.25 mg i.v. bolus)
Trial: 3276389
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care with combination chemotherapy
Trial: 26161468
Drug: Daily communication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily communication and language therapy
Trial: 26161468
Drug: Weekly therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly therapy sessions
Trial: 15706008
Drug: Cholesterol-rich diet
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-rich diet (800 mg/d cholesterol)
Trial: 15706008
Drug: Normal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal diet (250 mg/d cholesterol)
Trial: 12856482
Drug: Endogenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endogenous morphine synthesis
Trial: 10099861
Drug: Lamotrigine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (dose gradually increased in steps of 25 mg up to 100 mg per day)
Trial: 8733086
Drug: Aminophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5 mg.kg‐1)
Trial: 1751665
Drug: AST‐120 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST‐120 (oral adsorbent composed of spherical porous carbon particles)
Trial: 312708
Drug: morphine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (2 mg/kg)
Trial: 30852783
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) with human-assisted social robot
Trial: 30852783
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) without human-assisted social robot
Trial: 25927723
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg/d for 60 days)
Trial: 21266377
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment for 32 weeks
Trial: 21266377
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 32 weeks
Trial: 9502182
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rh-GH) 0.5-1.0 UIday(−1) s.c. at bed-time for 6 months
Trial: 9502182
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rh-GH)
Trial: 9256559
Drug: Psychodynamic‐interpersonal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic‐interpersonal therapy
Trial: 3175393
Drug: Anti-hypertensive agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive agents
Trial: 30987269
Drug: PD-1/PD-L1 blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 blockade therapies
Trial: 29161286
Drug: Control (Glasses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Glasses prescription only)
Trial: 23283526
Drug: Lapatinib 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,000 mg plus pazopanib 400 mg (Cohort 1)
Trial: 23283526
Drug: Lapatinib 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,500 mg monotherapy (Cohort 1)
Trial: 23283526
Drug: Lapatinib 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,500 mg plus pazopanib 800 mg (Cohort 2)
Trial: 18983661
Drug: High-dose acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acetaminophen (6 g daily for 3 days), started within 12 hours after symptom onset
Trial: 10193219
Drug: Cisatracurium 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.05 mg.kg‐1
Trial: 10193219
Drug: Mivacurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.15 mg.kg‐1
Trial: 31420647
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (200,000 IU initial dose followed by 100,000 IU monthly, n = 2558)
Trial: 26935961
Drug: Antibiotic CVCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic CVCs
Trial: 26935961
Drug: Heparin CVCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin CVCs
Trial: 17303041
Drug: Control preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control preparations (Vanicream and petrolatum)
Trial: 12049861
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (cisplatin 80 mg/m² by infusion over 4 h plus fluorouracil 1000 mg/m² daily by continuous infusion for 4 days) followed by surgical resection (CS group, n=400)
Trial: 8129118
Drug: Diazepam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.2 mg.kg‐1)
Trial: 8129118
Drug: Midazolam (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.07 mg.kg‐1)
Trial: 2530251
Drug: Acitretin 25
RxNorm normalized name: acitretin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin 25 to 75 mg daily during open study
Trial: 12680738
Drug: Ethanol (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (blood concentrations of approximately 80‐100 mg/100 ml)
Trial: 10731530
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg p.o.)
Trial: 2410328
Drug: ARA‐AMP 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARA‐AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days
Trial: 26926681
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² IV on day 1 of a 3-week cycle (arm A)
Trial: 26926681
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² IV plus ramucirumab 10 mg/kg IV on day 1 of a 3-week cycle (arm B)
Trial: 26926681
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of a 3-week cycle (arm C)
Trial: 22357725
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 20 g protein/d (20% pea, 20% soy, 30% egg, and 30% milk-protein isolate)
Trial: 22357725
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 20 g protein/d
Trial: 22357725
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 20 g maltodextrin/d
Trial: 20535042
Drug: Lateral decubitus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral decubitus position after caudal epidural injection (Group 1, n=28)
Trial: 20535042
Drug: Supine position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine position after caudal epidural injection (Group 2, n=29)
Trial: 18473409
Drug: N-acetyl-L-cysteine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine (0.8 g/d) plus mesalamine (2.4 g/d)
Trial: 15723220
Drug: Docetaxel alone
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel alone (treatment A)
Trial: 15723220
Drug: Docetaxel with
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel with aprepitant (treatment B)
Trial: 8782129
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 50,000 units/week and calcium 1,000 mg/day
Trial: 1419761
Drug: terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine 1% cream applied for 1 day
Trial: 1419761
Drug: terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine 1% cream applied for 3, 5, or 7 consecutive days
Trial: 1419761
Drug: terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine 1% cream applied for 7 days
Trial: 6371875
Drug: Trazodone (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (100-200 mg, nocte)
Trial: 6371875
Drug: Mianserin (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (60-120 mg, nocte)
Trial: 29983409
Drug: CCH injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCH injection
Trial: 29983409
Drug: ADH injection
RxNorm normalized name: ADH-503
DrugBank: ADH-503 (DB17133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADH injection
Trial: 27178983
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy for advanced NSCLC
Trial: 22429765
Drug: Combined strengthening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined strengthening, stretching and functional training program, 12 weeks, twice a week, 40-60 minutes each session.
Trial: 3541052
Drug: Naltrexone 100
RxNorm normalized name: naltrexone 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 100 mg daily
Trial: 17564278
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for at least two years
Trial: 17564278
Drug: Untreated patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated patients (refused CPAP therapy)
Trial: 10519674
Drug: Glucose, insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose, insulin and potassium
Trial: 2127257
Drug: Oral flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral flurbiprofen (150 mg)
Trial: 25160845
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diet and exercise (n = 117)
Trial: 19131655
Drug: Intervention (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (ranitidine infusion during flight)
Trial: 15025614
Drug: 90-min application
RxNorm normalized name: progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90-min application of Lidocaine/Prilocaine cream followed by a 30-min interval before cannulation (Group B)
Trial: 15025614
Drug: 60-min application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-min application of Lidocaine/Prilocaine cream followed by immediate cannulation (Group A)
Trial: 11561265
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine patient-controlled analgesia (PCA)
Trial: 9749274
Drug: rtPA (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rtPA (recombinant tissue plasminogen activator) administered at the pick-up point
Trial: 7848592
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of loperamide and diphenoxylate orally plus placebo subcutaneously for 10 days
Trial: 3228575
Drug: Tablet B
RxNorm normalized name: Biaxin 4 Tablet Blister Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet B (MOTRIN Tablet) 400 mg
Trial: 3228575
Drug: Tablet A
RxNorm normalized name: tablet administration aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet A (generic ibuprofen tablet) 400 mg
Trial: 3228575
Drug: Both Tablet
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Tablet A and Tablet B
Trial: 5448798
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline assessment before treatment)
Trial: 29231508
Drug: Drug local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug local block anesthesia (compound articaine hydrochloride injection)
Trial: 29231508
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Acupuncture and Drug)
Trial: 23969184
Drug: Octreotide implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide implant (84 mg)
Trial: 23969184
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR (10-40 mg)
Trial: 23969184
Drug: Octreotide implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide implant
Trial: 20436711
Drug: Clevudine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevudine (30 mg once daily)
Trial: 20436711
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg once daily)
Trial: 18486741
Drug: ASC plus
RxNorm normalized name: ASCE plus Derma Signal Kit SRLV KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC plus chemotherapy (MVP and vinorelbine combined)
Trial: 16813181
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with microorganism pharmaceutical preparations (Group A)
Trial: 16813181
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of medicine for loosening the bowel to relieve constipation plus microorganism pharmaceutical preparations (Group B)
Trial: 6379505
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg/d
Trial: 29431228
Drug: MAS063DP lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS063DP lotion
Trial: 29431228
Drug: 0.02% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% triamcinolone acetonide lotion
Trial: 26607831
Drug: Sodium butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium butyrate enemas (30ml of sodium butyrate 600mmol/L, b.i.d. for 30 days)
Trial: 22370739
Drug: Capadenoson 10
RxNorm normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capadenoson 10 mg
Trial: 22370739
Drug: Capadenoson 20
RxNorm normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capadenoson 20 mg
Trial: 22370739
Drug: Capadenoson (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capadenoson (various doses)
Trial: 19640572
Drug: Single-dose Change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose Change
Trial: 17851565
Drug: Baicalin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalin (50 mg tablets, three times daily for 14 days)
Trial: 15681300
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg twice daily)
Trial: 10511131
Drug: Doxazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days)
Trial: 8895264
Drug: HBOC-201 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC-201 (3 mL/kg)
Trial: 2049684
Drug: Nitrendipine 10
RxNorm normalized name: nitrendipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 10 mg bid
Trial: 6509877
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Trial: 6509877
Drug: Syrup containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Trial: 6509877
Drug: Single-ingredient tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-ingredient tablet of pseudoephedrine
Trial: 6509877
Drug: Single-ingredient tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-ingredient tablet of triprolidine
Trial: 28918732
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus pharmacotherapy (178 patients)
Trial: 28918732
Drug: Pharmacotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy alone (173 patients)
Trial: 25942472
Drug: Reduced Glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced Glycerin Vaginal Formulation (RGVF) gel - 7 daily doses
Trial: 25942472
Drug: Rectal Specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Specific Formulation (RF) gel - 7 daily doses
Trial: 25942472
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 6 daily doses followed by 1 dose of Vaginal Formulation (VF) gel
Trial: 19222623
Drug: Daptomycin 4
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 4 mg/kg once daily
Trial: 12624483
Drug: BT‐CoQ10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT‐CoQ10 (300 mg daily for 1 week)
Trial: 12624483
Drug: Commercial grade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial grade CoQ10 (300 mg daily for 1 week)
Trial: 11516000
Drug: Endopore dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endopore dental implants
Trial: 9145132
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (100% oxygen at 2.4 ATA, n = 6)
Trial: 8198274
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intravenous lidocaine
Trial: 8198274
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg intravenous lidocaine
Trial: 3542470
Drug: Cefazoline (Kefzol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazoline (Kefzol 0.5 g every six hours)
Trial: 3542470
Drug: Ceftriaxone (Rocephin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (Rocephin 2 g single dose)
Trial: 30241227
Drug: Adjuvant carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy
Trial: 27006549
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg intravenously
Trial: 27006549
Drug: Butorphanol 1
RxNorm normalized name: butorphanol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 1 mg intravenously
Trial: 27006549
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 3 ml intravenously (placebo)
Trial: 17985084
Drug: Preemptive warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive warfarin dose reduction (10‐20%)
Trial: 17985084
Drug: No change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No change in warfarin dosing (Control)
Trial: 17985084
Drug: Preemptive warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive warfarin dose reduction (10‐20%) with TMP‐SMX
Trial: 17985084
Drug: Preemptive warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive warfarin dose reduction (10‐20%) with levofloxacin
Trial: 12679925
Drug: Routine drugs
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drugs (VitC, aspartic acid)
Trial: 1400985
Drug: Cold-adapted influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted influenza B reassortant virus vaccine (doses ranging from 10(3.2) to 10(6.2) TCID50)
Trial: 1400985
Drug: Cold-adapted influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted influenza B reassortant virus vaccine
Trial: 29133606
Drug: Roux‐en‐Y gastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roux‐en‐Y gastric bypass plus medical therapy
Trial: 17135986
Drug: COMB (fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMB (fluoxetine + cognitive-behavioral therapy)
Trial: 17135986
Drug: FLX (fluoxetine)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FLX (fluoxetine)
Trial: 17135986
Drug: CBT (cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT (cognitive-behavioral therapy)
Trial: 10733540
Drug: Cisapride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (20 mg twice per day) for 1 week
Trial: 29076666
Drug: Topical Turpentine
RxNorm normalized name: turpentine
DrugBank: Turpentine (DB11120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Turpentine Oil
Trial: 19349130
Drug: Carbosylane (activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbosylane (activated charcoal-simethicone combination)
Trial: 9412397
Drug: Amoxycillin/potassium clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/potassium clavulanate (amoxyclav) 1.2 g IV every 8 hours for 2 days, then 625 mg orally thrice a day for 5 days